---
company: Faeth Therapeutics, Inc.
ticker: FTH
form: 8-K
filed: 2026-11-03
accepted: 2026-11-03T13:14:10+00:00
accession: 0001193125-26-444410
source: https://www.sec.gov/Archives/edgar/data/1829802/000119312526444410/
---

# Faeth Therapeutics (FTH) Q3 2026 earnings

## Header

- Company: Faeth Therapeutics, Inc.
- Reported: 2026-11-03 08:14 BMO ET
- Source: 8-K only — accession 0001193125-26-444410, Item 2.02 + Exhibit 99.1
- Verdict: Operating expenses increased 34.9% YoY to $22.09M, widening the net loss to $20.40M despite a 78.2% reduction in net loss per share.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---|---|---|
| Revenue | $0 | — | — | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $22,086K (+34.9% YoY)
- One-offs in the quarter: not stated in the 8-K
- Effective tax rate: not stated in the 8-K
- Non-GAAP bridge: not stated in the 8-K

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Research and development | $11,736K | $9,180K | $2,536K | +27.8% QoQ, +362.6% YoY |
| General and administrative | $10,350K | $9,205K | $2,315K | +12.5% QoQ, +346.9% YoY |
| Total other income | $1,688K | $2,378K | $282K | -29.0% QoQ, +498.6% YoY |
| Cash and cash equivalents | $14,180K | $26,903K | $8,668K | -47.3% QoQ, +63.5% YoY |
| Marketable securities | $160,615K | $159,538K | $12,516K | +0.7% QoQ, +1182.9% YoY |

## Guidance

not stated in the 8-K

## What drove it

- Revenue story: No revenue reported.
- EPS story: Net loss per share improved YoY due to a 1948.8% increase in weighted-average shares outstanding.
- One-off check: None reported.

## The good

- Net loss per share improved 78.2% YoY to -$0.79
- Marketable securities increased 1182.9% YoY to $160.6M

## The bad

- Operating expenses increased 34.9% YoY to $22.09M
- Cash and cash equivalents decreased 47.3% QoQ to $14.18M

## The ugly

- none

## Open questions

- What caused the 47.3% QoQ decline in cash and cash equivalents?
- What caused the 29.0% QoQ decline in total other income?

## Full release

### Faeth Therapeutics (FTH) earnings release, November 3, 2026

Faeth Therapeutics, Inc. (FTH) · Form 8-K, Item 2.02 · Filed 2026-11-03 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1829802/000119312526444410/)

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

AUSTIN, Texas—(BUSINESS WIRE)—November 3, 2026— Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones.

“Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2

PIK-201 trial and received Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer,” said Anand Parikh, Chief Executive Officer. “The PAM pathway is dysregulated in up to 50% of solid tumors, and feedback reactivation and resistance mutations may limit single-node inhibitors. We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option. We look forward to reading out topline data from our Phase 2

PIK-201 trial in endometrial cancer by year-end, and to reporting initial safety and efficacy data from our

PIK-101 trial in HR+/HER2- breast cancer in 2027.”

Recent Corporate Updates:

Third

Quarter 2026 Financial Results

Weighted-average common shares outstanding, basic and diluted, were 25,840,555 for the quarter ended September 30, 2026, compared with

1,261,290 for the quarter ended September 30, 2025.

Condensed Statements of Operations

(Unaudited, in thousands except share and per share data)

Selected Condensed Balance Sheet Data

(Unaudited, in thousands)

About PIKTOR

PIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. This multi-node approach is designed to address the signaling feedback reactivation and treatment-emergent resistance mutations that may limit the efficacy of single-node PI3K/AKT/mTOR pathway inhibitors. According to published literature, the PAM pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology.

PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study

FTH-PIK-201), with topline data anticipated by year-end

2026. PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study

FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.

About Faeth Therapeutics

Faeth Therapeutics, Inc.

(Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph.D., together with scientific founders Lewis Cantley, Ph.D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph.D.; Scott Lowe, Ph.D.; and Greg Hannon, Ph.D. The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.faeththerapeutics.com and follow the Company on

LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by words such as “anticipate,” “believe,” “expect,”

“intend,” “plan,” “may,” “will,” “would,” “could,” “should,” “estimate,” “potential,” “target,” “on track” and similar expressions, although not all forward-looking statements contain these words. These statements include, but are not limited to, statements regarding: the Company’s interpretation of preclinical, pharmacokinetic and pharmacodynamic data and the conclusions the Company draws from that data, including with respect to dose and schedule selection for PIKTOR and comparisons of PIKTOR’s preclinical profile to that of other tested inhibitors; the anticipated benefits of Fast Track

Designation; the Company’s expectations regarding its pipeline and development plans, including the Phase 2 trial of PIKTOR in advanced endometrial cancer and the anticipated timing of topline data, and the Phase 1b/2 trial of PIKTOR in

HR+/HER2- advanced breast cancer and the anticipated timing of interim data; the potential therapeutic benefits, tolerability profile and differentiation of PIKTOR; and the Company’s expectations regarding its cash runway.

Forward-looking statements are based on management’s current expectations and assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, risks related to clinical development and the conduct, timing and results of clinical trials; the risk that results from preclinical studies, including comparisons with other product candidates or approved products, earlier clinical trials, modeling or other exploratory analyses may not be predictive of results in ongoing or future clinical trials; risks related to reliance on third parties for the supply of investigational agents used in combination studies; the Company’s cash position and.ticipated cash runway; the Company’s need for additional financing; its limited operating history and history of operating losses; risks related to the integration of Faeth; the Company’s ability to satisfy applicable Nasdaq listing requirements and to maintain the listing of its common stock; and the other risks and uncertainties described under the headings “Risk Factors” and “Summary of Risk Factors” in the Company’s Annual Report on Form

10-K filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2026, its Quarterly Report on Form

10-Q filed with the SEC on November 3,

2026, and its definitive proxy statement filed with the SEC on April 27, 2026, as well as in the Company’s subsequent filings. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required by law.

View source version on businesswire.com:

[Insert Link]

Investor Contact:

Matthew Biegler, SVP, Investor

Relations matt@faeththerapeutics.com

Media

Contact:

Patrick Schmidt, Consort Partners faeththerapeutics@consortpartners.com

Source: Faeth

Therapeutics, Inc.

#### Financial statements

##### Income Statement (For the Three Months Ended September 30, — (Unaudited, in thousands except share and per share data))

| | For the Three Months Ended September 30, – 2026 | For the Three Months Ended September 30, – 2025 |
|---|---:|---:|
| **Operating expenses:** | | |
| Research and development | 11,736 | 2,536 |
| General and administrative | 10,350 | 2,315 |
| Total operating expenses | 22,086 | 4,851 |
| Loss from operations | -22,086 | -4,851 |
| Total other income | 1,688 | 282 |
| Net loss | -20,398 | -4,569 |
| Net loss per share, basic and diluted | -0.79 | -3.62 |
| Weighted-average common shares outstanding, basic and diluted | 25,840,555 | 1,261,290 |

##### Balance Sheet (September 30, 2026 — (Unaudited, in thousands))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Cash and cash equivalents | 14,180 | 8,668 |
| Marketable securities | 160,615 | 12,516 |
| Total assets | 178,949 | 22,902 |
| Total liabilities | 11,085 | 4,310 |
| Series B redeemable convertible preferred stock | 6,767 |  |
| Total stockholders’ equity | 161,097 | 18,592 |
